Helus Pharma names Intra-Cellular veterans to leadership and advisory roles

Helus Pharma, the operating name of Cybin Inc., announced on August 18, 2026 the appointment of Regina Donohue as Chief People Officer and the appointment of Suresh Durgam, M.D., to the Company's Scientific Advisory Board.¹

Donohue most recently served as Chief Human Resources Officer at Intra-Cellular, where she built the company's people strategy and infrastructure, and managed its rapid growth as it transitioned into a commercial-stage organization, launched its first product, and grew to 1,000+ employees.¹ Intra-Cellular was acquired by Johnson & Johnson in April 2025.¹ Earlier in her career, Donohue was among the first five executives hired to build LEO Pharma's U.S. subsidiary, establishing its human resource function and supporting the organization through the rapid growth necessary to launch two products in the U.S. During her tenure at LEO Pharma, she also served as the interim Global Head of Human Resources.¹

Durgam, who served as Executive Vice President and Chief Medical Officer at Intra-Cellular, played a pivotal role in securing FDA approvals for CAPLYTA across multiple indications, including schizophrenia, bipolar depression, as both a monotherapy and adjunctive therapy, and adjunctive major depressive disorder.¹ He previously held clinical-development leadership roles at Allergan, Forest Laboratories and Solvay Pharmaceuticals, and his development experience includes lumateperone, cariprazine, vilazodone, levomilnacipran and other CNS therapies.¹

The company describes itself as a clinical stage pharmaceutical company committed to helping minds heal by developing proprietary NSAs, synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity.¹ Its pipeline includes HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of MDD that has received Breakthrough Therapy Designation from the FDA, and HLP004, also a proprietary NSA in Phase 2 for GAD.¹